tiprankstipranks
Advertisement
Advertisement

RAPP Stock Latest News

Rapport Therapeutics management to meet with Citizens
The FlyRapport Therapeutics management to meet with Citizens
2h ago
RAPP
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting
PremiumCompany Announcements
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting
6d ago
8K
RAPP
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy
PremiumCompany Announcements
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy
12d ago
RAPP
Rapport Therapeutics price target raised to $65 from $53 at BTIG
PremiumThe Fly
Rapport Therapeutics price target raised to $65 from $53 at BTIG
26d ago
RAPP
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
PremiumRatings
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
29d ago
RAPP
Rapport Therapeutics assumed with a Buy at Truist
PremiumThe FlyRapport Therapeutics assumed with a Buy at Truist
29d ago
RAPP
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
Premium
Ratings
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
1M ago
RAPP
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
Premium
Company Announcements
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
1M ago
RAPP
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
PremiumThe Fly
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
1M ago
RAPP
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
PremiumCompany Announcements
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
2M ago
8K
RAPP
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
PremiumThe Fly
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
2M ago
RAPP
Rapport Therapeutics initiated with a Strong Buy at Raymond James
PremiumThe Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
2M ago
RAPP
Closing Bell Movers: Markets on edge ahead of US-Iran talks
PremiumThe FlyClosing Bell Movers: Markets on edge ahead of US-Iran talks
2M ago
FGI
SLP
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
2M ago
RAPP
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
2M ago
RAPP
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
PremiumRatings
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
3M ago
RAPP
Rapport Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Rapport Therapeutics files automatic mixed securities shelf
3M ago
RAPP
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
PremiumThe Fly
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
3M ago
RAPP
Rapport Therapeutics sees cash runway into 2H29
PremiumThe Fly
Rapport Therapeutics sees cash runway into 2H29
3M ago
RAPP
Rapport, Tenacia announce collaboration for RAP-219 in Greater China
PremiumThe FlyRapport, Tenacia announce collaboration for RAP-219 in Greater China
3M ago
RAPP
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
Premium
Company Announcements
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
4M ago
RAPP
Rapport Therapeutics initiated with an Overweight at Wells Fargo
Premium
The Fly
Rapport Therapeutics initiated with an Overweight at Wells Fargo
4M ago
RAPP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >